Jun Wang

Has grant

Associate Professor

Rutgers University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jun Wang is an Associate Professor at Rutgers The State University of New Jersey. His research focuses on virology, particularly in the areas of influenza and SARS-CoV-2, with recent articles highlighting the design of protease inhibitors and the study of viral resistance. His work employs various methodologies, including structural studies and yeast-based systems, to better understand viral mechanisms and develop effective treatments.

Recent Grants

Grant: Close

High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A Proteases

Open Date: 2019-06-07

Close Date: 2023-05-31

Grant: Close

Discovery of broad-spectrum influenza antivirals with a high genetic barrier to drug resistance by targeting the viral polymerase

Open Date: 2019-03-01

Close Date: 2021-02-28

Grant: Close

Drug Discovery Targeting the Influenza A Virus M2-S31N Proton Channel

Open Date: 2015-07-06

Close Date: 2020-06-30

Grant: Close

Drug Discovery Targeting the Influenza A Virus M2-S31N Proton Channel

Open Date: 2015-07-01

Close Date: 2017-06-30

Articles (20)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (7)

Eddy Arnold

Rutgers University

UNITED STATES

View details

Xufang Deng

Assistant professor

Oklahoma State University

UNITED STATES

View details

Kan Li

Teaching Assistant

Rutgers University

UNITED STATES

View details

Santiago Vazquez

Full professor

University of Barcelona

SPAIN

View details

Eric Lewandowski

University of South Florida

UNITED STATES

View details

Jialin zhang

Fred Hutch Cancer Center

UNITED STATES

View details

Hongmin Li

R. Ken and Donna Coit Endowed Chair Professor

University of Arizona

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jun Wang

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Bat Influenza M2 Shows Functions Similar to Those of Classical Influenza A Viruses

Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model

Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model

Structure-based design of SARS-CoV-2 papain-like protease inhibitors

An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses

A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid-State NMR**

A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir.

Hexamethylene amiloride binds the SARS-CoV-2 envelope protein at the protein-lipid interface.

A yeast-based system to study SARS-CoV-2 M<SUP>pro</SUP> structure and to identify nirmatrelvir resistant mutations

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir

Stereospecific Effects of Benzimidazolonepiperidine Compounds on T-Type Ca<sup>2+</sup> Channels and Pain

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor

Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease

Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor

AG1478 Elicits a Novel Anti-Influenza Function via an EGFR-Independent, GBF1-Dependent Pathway

Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell

The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition

Editorial of Special Column on Antiviral Drug Discovery and Pharmacology

Enterovirus A71 antivirals: Past, present, and future

Collaborators (7)

Eddy Arnold

Xufang Deng

Kan Li

Santiago Vazquez

Eric Lewandowski

Jialin zhang

Hongmin Li

Make your next move.